A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

Saved in:
Bibliographic Details
Title: A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Authors: Bonnefoi, H.1 h.bonnefoi@bordeaux.unicancer.fr, Grellety, T.1, Tredan, O.2, Saghatchian, M.3, Dalenc, F.4, Mailliez, A.5, L'Haridon, T.6, Cottu, P.7, Abadie-Lacourtoisie, S.8, You, B.9, Mousseau, M.10, Dauba, J.11, Del Piano, F.12, Desmoulins, I.13, Coussy, F.14, Madranges, N.1, Grenier, J.15, Bidard, F. C.7, Proudhon, C.7, MacGrogan, G.16
Source: Annals of Oncology. May2016, Vol. 27 Issue 5, p812-818. 7p. 1 Diagram, 4 Charts.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdw067